Q2 EPS Forecast for CRISPR Therapeutics Raised by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at William Blair boosted their Q2 2025 EPS estimates for CRISPR Therapeutics in a report released on Monday, July 14th. William Blair analyst S. Corwin now expects that the company will earn ($1.48) per share for the quarter, up from their prior forecast of ($2.27). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. William Blair also issued estimates for CRISPR Therapeutics’ FY2025 earnings at ($6.18) EPS and FY2026 earnings at ($3.29) EPS.

Other equities analysts also recently issued research reports about the company. Needham & Company LLC reissued a “buy” rating and set a $81.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, July 8th. The Goldman Sachs Group cut their price objective on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a research report on Thursday, May 8th. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Wall Street Zen raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Friday, May 16th. Finally, Piper Sandler reiterated an “overweight” rating and set a $105.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Two analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $71.75.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $55.14 on Wednesday. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $63.39. The business’s 50 day moving average is $43.70 and its two-hundred day moving average is $41.57. The stock has a market capitalization of $4.76 billion, a P/E ratio of -12.20 and a beta of 1.82.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. The company’s quarterly revenue was up 71.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.43) EPS.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the firm’s stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total transaction of $141,316.08. Following the transaction, the insider directly owned 6,068 shares in the company, valued at $218,083.92. This trade represents a 39.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CRSP. Ipswich Investment Management Co. Inc. raised its holdings in shares of CRISPR Therapeutics by 1.7% in the second quarter. Ipswich Investment Management Co. Inc. now owns 24,968 shares of the company’s stock valued at $1,214,000 after acquiring an additional 425 shares in the last quarter. Perigon Wealth Management LLC raised its holdings in shares of CRISPR Therapeutics by 9.2% in the 2nd quarter. Perigon Wealth Management LLC now owns 18,312 shares of the company’s stock valued at $891,000 after purchasing an additional 1,538 shares in the last quarter. AdvisorNet Financial Inc raised its holdings in shares of CRISPR Therapeutics by 20.9% in the 2nd quarter. AdvisorNet Financial Inc now owns 6,133 shares of the company’s stock valued at $298,000 after purchasing an additional 1,060 shares in the last quarter. Bouvel Investment Partners LLC lifted its position in shares of CRISPR Therapeutics by 43.6% in the 2nd quarter. Bouvel Investment Partners LLC now owns 31,161 shares of the company’s stock worth $1,516,000 after purchasing an additional 9,458 shares during the period. Finally, Farther Finance Advisors LLC boosted its stake in shares of CRISPR Therapeutics by 43.8% during the second quarter. Farther Finance Advisors LLC now owns 8,093 shares of the company’s stock valued at $394,000 after purchasing an additional 2,467 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.